Skip to content
Sub practice
Sub practice

Merger Control

We advise many of the world's most sophisticated businesses on their merger control strategies.

Our purpose is to create value for our clients by supporting them on winning regulatory approval of private mergers and acquisitions, public takeovers, joint ventures, cooperation or distribution agreements and disposals.

Our merger control team is an integral part of Allen & Overy’s Corporate practice which, in the last five years, has advised on more than 1,360 M&A deals worth over GBP730 billion, according to Mergermarket. Our clients can be confident that we will provide the highest quality of strategic merger control advice.

Having acted on some of the most pioneering transactions in recent years, we are expert in advising on complex, multi-jurisdictional mergers involving in-depth regulatory scrutiny and remedy negotiation. The practice is renowned for its experience in guiding multinational companies through complex and sensitive phase I and phase II merger control cases, before the European Commission, Department of Justice, Federal Trade Commission and other (inter)national regulators. We have extensive experience working on multi-jurisdictional merger control strategies and filings, with a cross-border network of specialists further supplemented by a wide network of local referral firms.

Through our work on ground-breaking cases we are able to draw on our knowledge of novel strategies and complex issues at the forefront of antitrust policy to deliver value to our clients and minimise the risk in any merger control execution process.

  • Winner 2015, Merger Control Matter of the Year (Asia-Pacific, Middle East and Africa) Global Competition Review awards
  • Winner 2012, Merger Control Matter of the Year (Asia-Pacific, Middle East and Africa) Global Competition Review awards
  • Winner 2012, Matter of the Year, Global Competition Review awards
  • Winner 2011, Matter of the Year, Global Competition Review awards

 

News and insights

Curved modern building

Publications: 13 March 2024

Immunity and leniency pipeline continues general decline

Overall, the number of immunity/leniency cases decided in 2023 (19) was broadly in line with 2022 (18), although lower than both 2021 (32) and 2020 (31). The costs and uncertainty associated with…

Read more
Blue sky between two modern skyscrapers

News: 28 February 2024

Antitrust authorities continue intense scrutiny in M&A markets

Antitrust authorities continued to have a big impact on M&A in 2023, frustrating more deals and intensifying scrutiny of digital and private equity transactions, reveals A&O’s latest Global Trends in…

Read more
Skyscrapers against a blue sky

Publications: 28 February 2024

Tougher merger control enforcement frustrates more M&A

Antitrust authorities frustrated more deals in 2023, adopting an increasingly tough approach to merger control enforcement. They used novel arguments to challenge transactions, continued to reject…

Read more
Skyscrapers against a blue sky

Publications: 28 February 2024

Antitrust authorities remain unwilling to accept merger remedies

The trend of favouring prohibition over remedies continued in 2023, at least in certain jurisdictions, eg the U.S., where agencies remained sceptical of whether behavioural or even structural remedies…

Read more

Related content

Recognition